ReviewCurrent medicinal chemistry2025
Exploring the Multitarget Therapeutic Potential of Mangostin Derivatives.
Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Mangostins and their derivatives exhibit broad therapeutic potential, with structural modifications enhancing their efficacy against cancer, inflammation, neurodegenerative disorders, oxidative stress, and microbial infections. Modified derivatives have demonstrated improved effectiveness in cancer treatment. They exhibit potent anti- inflammatory effects for conditions like pulmonary fibrosis and Parkinson's disease and neuroprotective benefits through cholinesterase inhibition and protection against oxidative damage. For example, structural modifications of α-mangostin (1) significantly enhanced its cytotoxicity, with the 3,6-dibenzylated (4) derivative achieving three times greater efficacy against HL-60 cells and diacetyl (8) and benzoyl (9) derivatives and two- and four-fold improvements against HT-29 cells. The enhanced antioxidant properties of these derivatives improve radical scavenging, lipid protection, and metal ion binding. They possess antimicrobial properties against multidrug-resistant bacteria and fungi, with several derivatives exhibiting high membrane selectivity, low toxicity, and strong in vivo efficacy. Their antimalarial, antiparasitic, and antiviral activities further expand their therapeutic uses, including inhibition of viral proteases. Structural modifications of α-mangostin (1) show promising clinical applications, including enhanced cytotoxicity in cancer therapy with the 3,6-dibenzylated (4), diacetyl (8), and benzoyl (9) derivatives, potent anti-inflammatory activity with PDE4-targeting compound (43), and effective antimicrobial properties in derivatives (18 and 22) against multidrug-resistant infections.
Indexed as
Identifiers
40457979What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.